{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:38:25Z","timestamp":1793911105776,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eisai Inc."},{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a known inhibitor of VEGF receptors 1\u20133, FGFRs 1\u20134, and PDGFR-\u03b1) was evaluated for second-line treatment of BTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single-arm, multicenter, open-label, phase 2 study, patients with BTC received lenvatinib 24\u2009mg orally once daily in 28-day\u2009cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), PFS rate at 12\u2009weeks, disease control rate, clinical benefit rate, safety and pharmacokinetic profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six Japanese patients were enrolled and treated; 3 had a confirmed partial response per investigator assessment and per independent imaging review (IIR); ORR was 11.5% (90% confidence interval [CI]: 3.2\u201327.2). Median PFS was 3.19\u2009months (95% CI: 2.79\u20137.23) per investigator assessment and 1.64\u2009months (95% CI: 1.41\u20133.19) per IIR. Median OS was 7.35\u2009months (95% CI: 4.50\u201311.27). Grade\u2009\u2265\u20093 treatment-emergent adverse events (TEAEs) occurred in 21 patients (80.8%) and included hypertension (<jats:italic>n<\/jats:italic>\u2009=\u200910 [38.5%]), proteinuria (<jats:italic>n<\/jats:italic>\u2009=\u20093 [11.5%]), palmar-plantar erythrodysesthesia (n\u2009=\u20093 [11.5%]), decreased appetite (n\u2009=\u20093 [11.5%]), and anemia (n\u2009=\u20093 [11.5%]). Two deaths occurred due to TEAEs between treatment initiation and 30\u2009days after last dose, but neither were considered treatment related.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lenvatinib demonstrated antitumor activity in BTC, with a tolerable safety profile, and should be further evaluated as potential second-line therapy for this difficult to treat population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579616\">NCT02579616<\/jats:ext-link>. Date of registration: October 19, 2015.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07365-4","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T10:06:22Z","timestamp":1605521182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results"],"prefix":"10.1186","volume":"20","author":[{"given":"Makoto","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Hayata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"7365_CR1","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/CMAR.S157092","volume":"11","author":"NU Tariq","year":"2019","unstructured":"Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623\u201342.","journal-title":"Cancer Manag Res"},{"key":"7365_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/cco.2016.10.09","volume":"5","author":"L Marcano-Bonilla","year":"2016","unstructured":"Marcano-Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol. 2016;5:61.","journal-title":"Chin Clin Oncol"},{"key":"7365_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/cncr.31942","volume":"125","author":"AL Van Dyke","year":"2019","unstructured":"Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer. 2019;125:1489\u201398.","journal-title":"Cancer."},{"key":"7365_CR4","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hepatobiliary Cancers. Version 4.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. Accessed 3 Jan 2020."},{"key":"7365_CR5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"key":"7365_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4143\/crt.2014.308","volume":"47","author":"JO Park","year":"2015","unstructured":"Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, et al. Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat. 2015;47:343\u201361.","journal-title":"Cancer Res Treat"},{"key":"7365_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/02656736.2020.1763484","volume":"27","author":"G Brandi","year":"2020","unstructured":"Brandi G, Rizzo A, Dall\u2019Olio FG, Felicani C, Ercolani G, Cescon M, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperth. 2020;27:479\u201385.","journal-title":"Int J Hyperth"},{"key":"7365_CR8","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 8","key":"7365_CR9","first-page":"Abstract 6150","volume":"29","author":"D Sakai","year":"2018","unstructured":"Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA) [abstract]. Ann Oncol. 2018;29(Suppl 8):Abstract 6150.","journal-title":"Ann Oncol"},{"key":"7365_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","volume":"98","author":"D Yoshikawa","year":"2008","unstructured":"Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418\u201325.","journal-title":"Br J Cancer"},{"key":"7365_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ejso.2003.09.013","volume":"29","author":"A Giatromanolaki","year":"2003","unstructured":"Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol. 2003;29:879\u201383.","journal-title":"Eur J Surg Oncol"},{"key":"7365_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2014.02.050","volume":"446","author":"YF Xu","year":"2014","unstructured":"Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun. 2014;446:54\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"7365_CR13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s13277-012-0438-8","volume":"33","author":"S Boonjaraspinyo","year":"2012","unstructured":"Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol. 2012;33:1785\u2013802.","journal-title":"Tumour Biol"},{"key":"7365_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"7365_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","volume":"340","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340:97\u2013103.","journal-title":"Cancer Lett"},{"key":"7365_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"7365_CR17","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"key":"7365_CR18","unstructured":"Eisai Co., Ltd. Eisai and MSD Japan commence collaboration on commercialization activities for Lenvima\u00ae (lenvatinib) in Japan [press release]. Published October 22, 2018. https:\/\/www.eisai.com\/news\/2018\/news201888.html. Accessed 3 Jan 2020."},{"issue":"Suppl 5","key":"7365_CR19","first-page":"246. Abstract 7","volume":"28","author":"M Ikeda","year":"2017","unstructured":"Ikeda M, Sasaki T, Morizane C, Mizuno N, Nagashima F, Shimizu S, et al. A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results [abstract]. Ann Oncol. 2017;28(Suppl 5):246. Abstract 722P.","journal-title":"Ann Oncol"},{"key":"7365_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","volume":"36","author":"M Nagahama","year":"2019","unstructured":"Nagahama M, Ozeki T, Suzuki A, Sugino K, Niioka T, Ito K, et al. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 2019;36:39.","journal-title":"Med Oncol"},{"key":"7365_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/bjc.2014.190","volume":"110","author":"L Fornaro","year":"2014","unstructured":"Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165\u20139.","journal-title":"Br J Cancer"},{"issue":"15 Suppl","key":"7365_CR22","doi-asserted-by":"publisher","first-page":"Abstract 4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","volume":"37","author":"A Lamarca","year":"2019","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy [abstract]. J Clin Oncol. 2019;37(15 Suppl):Abstract 4003.","journal-title":"J Clin Oncol"},{"key":"7365_CR23","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.21873\/anticanres.14282","volume":"40","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Ricci AD, Tober N, Nigro MC, Mosca M, Palloni A, et al. Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res. 2020;40:3013\u201330.","journal-title":"Anticancer Res"},{"key":"7365_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41416-019-0698-9","volume":"122","author":"A Belkouz","year":"2020","unstructured":"Belkouz A, de Vos-Geelen J, Math\u00f4t RAA, Eskens FALM, van Gulik TM, van Oijen MGH, et al. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer. 2020;122:634\u20139.","journal-title":"Br J Cancer"},{"issue":"Suppl 5","key":"7365_CR25","first-page":"Abstract LBA10_","volume":"30","author":"GK Abou-Alfa","year":"2019","unstructured":"Abou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubner S, Adeva J, et al. ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation [abstract]. Ann Oncol. 2019;30(Suppl 5):Abstract LBA10_PR.","journal-title":"Ann Oncol"},{"key":"7365_CR26","doi-asserted-by":"publisher","first-page":"17246","DOI":"10.18632\/oncotarget.12825","volume":"8","author":"X Luo","year":"2017","unstructured":"Luo X, Jia W, Huang Z, Li X, Xing B, Jiang X, et al. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. Oncotarget. 2017;8:17246\u201357.","journal-title":"Oncotarget."},{"key":"7365_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cncr.31872","volume":"125","author":"W Sun","year":"2019","unstructured":"Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125:902\u20139.","journal-title":"Cancer."},{"key":"7365_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2011.11.017","volume":"48","author":"JH Yi","year":"2012","unstructured":"Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2012;48:196\u2013201.","journal-title":"Eur J Cancer"},{"key":"7365_CR29","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","volume":"30","author":"AB El-Khoueiry","year":"2012","unstructured":"El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Investig New Drugs. 2012;30:1646\u201351.","journal-title":"Investig New Drugs"},{"issue":"12 Suppl 2","key":"7365_CR30","doi-asserted-by":"crossref","first-page":"Abstract A92","DOI":"10.1158\/1535-7163.TARG-15-A92","volume":"14","author":"Y Kato","year":"2015","unstructured":"Kato Y, Tabata K, Hori Y, Tachino S, Okamoto K, Matsui J. Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors [abstract]. Mol Cancer Ther. 2015;14(12 Suppl 2):Abstract A92.","journal-title":"Mol Cancer Ther"},{"key":"7365_CR31","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14:e0212513.","journal-title":"PLoS One"},{"key":"7365_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1186\/s12885-015-1795-7","volume":"15","author":"G Atanasov","year":"2015","unstructured":"Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, Brandl A, et al. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015;15:790.","journal-title":"BMC Cancer"},{"issue":"4 Suppl","key":"7365_CR33","doi-asserted-by":"publisher","first-page":"Abstract 500","DOI":"10.1200\/JCO.2018.36.4_suppl.500","volume":"36","author":"J Lin","year":"2018","unstructured":"Lin J, Shi W, Zhao S, Hu J, Hou Z, Yao M, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing [abstract]. J Clin Oncol. 2018;36(4 Suppl):Abstract 500.","journal-title":"J Clin Oncol"},{"key":"7365_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330.","journal-title":"N Engl J Med"},{"key":"7365_CR35","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473\u201382.","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"7365_CR36","doi-asserted-by":"publisher","first-page":"Abstract 5520","DOI":"10.1200\/jco.2013.31.15_suppl.5520","volume":"31","author":"I Vergote","year":"2013","unstructured":"Vergote I, Teneriello M, Powell MA, Miller DS, Garcia AA, Mikheeva ON, et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes [abstract]. J Clin Oncol. 2013;31(15 Suppl):Abstract 5520.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07365-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T05:26:56Z","timestamp":1669613216000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7365"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07365-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center at 5\u20131-1, Tsukiji, Chuo-ku, Tokyo, 104\u20130045, Japan (serial number: T4234). All patients provided written informed consent. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practices, and local ethical\/legal requirements.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Makoto Ueno: reports honoraria from Taiho Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Lilly, Teijin Pharma, Shire, Ono Pharmaceutical, and Merck Serono; consulting or advisory role for Shire; research funding from Taiho Pharmaceutical, Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono, NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals, and Yakult Honsha.Masafumi Ikeda: reports honoraria from Abbott, Bayer, Bristol Myers Squibb, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Nobelpharma, Novartis, Otsuka, Taiho Pharmaceutical, Teijin Pharma, and Yakult Honsha; consulting or advisory role for Bayer, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, MSD, NanoCarrier, Novartis, Shire, Teijin Pharma, and Eli Lilly; research funding from ASLAN Pharmaceuticals, AstraZeneca, Baxalta\/Shire, Bayer, Bristol Myers Squibb, Chugai Pharma, Eisai, Kowa, Kyowa Hakko Kirin, Lilly, Merck Serono, MSD, NanoCarrier, Novartis, Ono Pharmaceutical, Taiho Pharmaceutical, Takara Bio, and Yakult Honsha.Takashi Sasaki: reports honoraria from Taiho Pharmaceutical and Eisai.Fumio Nagashima: reports honoraria from ASKA pharma, Chugai Pharma, Hisamitsu, Kyowa Hakko Kirin, Merck Serono, Mochida, Ono Pharmaceutical, Shionogi, Taiho Pharmaceutical, Takeda, and Yakult Honsha; research funding from AstraZeneca, Baxalta, Bayer, Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, J Pharma, Kyowa Hakko Kirin, Merck Serono, MSD, NanoCarrier, Mochida, Ono Pharmaceutical, Pfizer, Sanofi, Takeda, Yakult Honsha, and Zeria Pharma.Nobumasa Mizuno: reports grants from Eisai, Merck Serono, AstraZeneca, Zeria Pharma, NanoCarrier, MSD, Dainippon Sumitomo Pharma, Novartis, ASLAN Pharmaceuticals, Incyte, Yakult Honsha, Pharma Valley Center, and Taiho Pharmaceutical; personal fees from Novartis, Yakult Honsha, Ono Pharmaceutical, OncoTherapy Science, Inc., Kyowa Hakko Kirin, Pfizer, Teijin Pharma and Taiho Pharmaceutical; non-financial support from Novartis, Yakult Honsha, Pfizer, and Bristol Myers Squibb.Satoshi Shimizu: reports research funding from NanoCarrier, Eisai, Baxalta, Taiho Pharmaceutical, Dainippon Sumitomo Pharma, AstraZeneca, IQVIA services Japan K.K., and Incyte.Hiroki Ikezawa: is an employee of Eisai Co., Ltd.Nozomi Hayata: is an employee of Eisai Co., Ltd.Ryo Nakajima: is an employee of Eisai Inc.Chigusa Morizane: reports honoraria from Taiho Pharmaceutical, MSD, Novartis, Teijin Pharma, Yakult Honsha, and Ono Pharmaceutical; consulting or advisory role for AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, MSD, Yakult Honsha, AbbVie, and Novartis; research funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J Pharma, Pfizer, AstraZeneca, and Merck Biopharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1105"}}